Results 111 to 120 of about 2,071 (176)

Bimekizumab for refractory hidradenitis suppurativa and associated inflammatory arthropathies. [PDF]

JAAD Case Rep
Tolete C, Tolete R, Friedman A, Tjahjono L.   +3 more
europepmc   +1 more source

The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy. [PDF]

Med Sci (Basel)
Lemiesz P, Nowowiejska-Purpurowicz J, Kaminski TW, Flisiak I.   +3 more
europepmc   +1 more source

Predictors of early high-level response to bimekizumab in patients with moderate-to-severe plaque psoriasis: a real-world cohort study. [PDF]

An Bras Dermatol
Engin B, Demir Y, Yildirim G, Diken FZ, Yildiz B, Kutlubay Z, Serdaroglu S.   +6 more
europepmc   +1 more source

Psychiatric safety of bimekizumab versus interleukin-23 inhibitors in psoriasis: A real-world TriNetX cohort study. [PDF]

JAAD Int
Tolete C, Friedman A, Calderon J, Tjahjono L.   +3 more
europepmc   +1 more source

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison. [PDF]

Rheumatol Ther
Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB.   +8 more
europepmc   +1 more source

Medical and Surgical Management of Hidradenitis Suppurativa. [PDF]

J Clin Med
Frew JW, Bechara FG.
europepmc   +1 more source

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. [PDF]

RMD Open
Mease PJ, Merola JF, Magrey M, Nash P, Poddubnyy D, Lebwohl M, Bajracharya R, Ink B, Marten A, Manente M, Peterson L, White K, Gensler LS.   +12 more
europepmc   +1 more source

Certolizumab pegol induced paradoxical psoriatic alopecia with therapeutic response to bimekizumab. [PDF]

An Bras Dermatol
Taş Aygar G, Keleş F, Biber FE, Han U, Kartal SP.   +4 more
europepmc   +1 more source

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study. [PDF]

J Eur Acad Dermatol Venereol
Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J, BE SHINING Study Group.   +11 more
europepmc   +1 more source

A tale of two meta-analyses: Similarity, consistency and avoiding overinterpretation in network meta-analysis. [PDF]

J Eur Acad Dermatol Venereol
Shourick J, Garbayo-Salmons P.
europepmc   +1 more source